Generic Versus Disease-Specific Patient Reported Outcome Instruments for Assessing Health-Related Quality of Life Burden Among Patients Diagnosed with Alopecia Areata: Evidence from TARGET-DERM AA

The study investigates the effectiveness of generic versus disease-specific patient-reported outcome instruments in assessing health-related quality of life (HRQoL) among 141 patients with alopecia areata (AA). The analysis compared the Short-Form 36 (SF-36), the Dermatology Life Quality Index (DLQI), and the Alopecia Areata Patient Priority Outcomes (AAPPO) across different severity groups defined by the Severity of Alopecia Tool (SALT) score. Results showed that generic QoL instruments like SF-36 and DLQI did not effectively capture differences in HRQoL among patients with varying AA severity. In contrast, the AAPPO, particularly its hair loss and activity limitation domains, demonstrated significant differences between patient subgroups, highlighting its sensitivity to AA-specific impacts on quality of life.